Reported Earlier, Roche's Genentech Announced Data From Stage 1 Of The National Institutes Of Health (NIH)-Sponsored Pivotal Phase III Outmatch Study Evaluating The Efficacy And Safety Ofxolair
Reported Earlier, Roche's Genentech Announced Data From Stage 1 Of The National Institutes Of Health (NIH)-Sponsored Pivotal Phase III Outmatch Study Evaluating The Efficacy And Safety Ofxolair
早些時候報道，羅氏基因泰克公佈了美國國立衛生研究院（NIH）贊助的評估Ofxolair療效和安全性的關鍵性III期勝出研究第一階段的數據
– Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction –
— 美國國立衛生研究院贊助的III期OutMatch研究的詳細結果顯示，使用Xolair進行治療可增加年僅1歲的人在沒有過敏反應的情況下食用的花生、木本堅果、雞蛋、牛奶和小麥的攝入量 —
– The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies –
— 美國食品藥品管理局最近批准Xolair作爲第一種也是唯一一種針對一種或多種食物過敏的兒童和成人的藥物—
– Allergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year –
— 過敏反應可能危及生命，據估計，與食物相關的過敏反應每年導致美國急診室治療30,000起醫療事件 —